Single-dose varicella vaccine effectiveness in Brazil: a case-control study

dc.creatorAndrade, Ana Lúcia Sampaio Sgambatti de
dc.creatorVieira, Maria Aparecida da Silva
dc.creatorMinamisava, Ruth
dc.creatorToscano, Cristiana Maria
dc.creatorSouza, Menira Borges de Lima Dias e
dc.creatorFiaccadori, Fabíola Souza
dc.creatorFigueiredo, Cristina Adelaide
dc.creatorCurti, Suely Pires
dc.creatorNerger, Maria Ligia Bacciotte Ramos
dc.creatorBierrenbach, Ana Luiza de Souza
dc.date.accessioned2024-08-22T13:57:36Z
dc.date.available2024-08-22T13:57:36Z
dc.date.issued2018
dc.description.abstractBackground: Varicella vaccine was introduced into the Brazilian Immunization Program in October 2013, as a single-dose schedule administered at 15 months of age. Its effectiveness had not yet been assessed in the country. Methods: A matched case-control study was carried out in São Paulo and Goiânia (Southeast and Midwest regions, respectively), Brazil. Suspected cases, were identified through a prospective surveillance estab lished in the study sites. All cases had specimens from skin lesion collected for molecular laboratory test ing. Cases were confirmed by either clinical or PCR of skin lesions and classified as mild, moderate, and severe disease. Methods: Two neighborhood controls were selected for each case. Cases and controls were aged 15–32 months and interviewed at home. Evidence of prior vaccination was obtained from vaccination cards. Univariate and multivariate logistic regression models were used, and odds ratio and its respective 95% confidence intervals were estimated. Vaccine effectiveness was estimated by comparing de odds of having received varicella vaccine among cases and controls. Results: A total of 168 cases and 301 controls were enrolled. Moderate and severe illness, was found in 33.3% and 9.9% of the cases. Effectiveness of a single dose varicella vaccine was 86% (95%CI 72–92%) against disease of any severity and 93% (95%CI 82–97%) against moderate and severe disease. Out of 168 cases, 81.8% had positive PCR results for wild-type strains, and 22.0% were breakthrough varicella cases. Breakthrough cases were milder compared to non-breakthrough cases (p < .001). Conclusions: Effectiveness of single dose varicella vaccine in Brazil is comparable to that in other coun tries where breakthrough varicella cases have also been found to occur. The goal of the varicella vaccina tion program, along with disease burden and affordability should be taken into consideration when considering the adoption of a second dose of varicella vaccine into national immunization programs. 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.identifier.citationANDRADE, Ana Lucia et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine, Amsterdam, v. 36, n. 4, p. 479-483, 2018. DOI: 10.1016/j.vaccine.2017.12.011. Disponível em: https://www.sciencedirect.com/science/article/pii/S0264410X17317516?via%3Dihub. Acesso em: 12 ago. 2024.
dc.identifier.doi10.1016/j.vaccine.2017.12.011
dc.identifier.issn0264-410X
dc.identifier.urihttp://repositorio.bc.ufg.br//handle/ri/25371
dc.language.isoeng
dc.publisher.countryHolanda
dc.publisher.departmentInstituto de Patologia Tropical e Saúde Pública - IPTSP (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectVaricella vaccination
dc.subjectBreakthrough
dc.subjectUniversal routine vaccination
dc.subjectVaccine effectiveness
dc.titleSingle-dose varicella vaccine effectiveness in Brazil: a case-control study
dc.typeArtigo

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Artigo - Ana Lúcia Sampaio Sgambatti de Andrade - 2018.pdf
Tamanho:
278.33 KB
Formato:
Adobe Portable Document Format
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: